BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Interferons (alpha), Peginterferon, Ropeginterferon

RISK OF SERIOUS DISORDERS

Risk of Serious Disorders

  • Alpha interferons, including peginterferon alfa-2a, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.
  • Patients should be monitored closely with periodic clinical and laboratory evaluations.
  • Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions.
  • In many, but not all cases, these disorders resolve after stopping therapy

MONITORING RECOMMENDATIONS RELATED TO BLACK BOX DATA

  • Close monitoring of depressive symptomatology and periodic neuropsychiatric evaluation during therapy.
  • Persistent severe or worsening signs or symptoms may necessitate discontinuation of therapy

Patient Counseling Information

Medication Guides

Patient Medication Guide - Itron A (Interferon Alfa-2b)

Patient Medication Guide - BESREMI (Ropeginterferon Alfa-2b-Nift)

Package Inserts

Interferons and Peginterferons

Updated December 2021